Background and Objectives: PIN1 is overexpressed in several human cancers, including prostate cancer, breast cancer, and oral squamous carcinomas. Juglone (J), derived from walnut, was reported to selectively inhibit PIN1 by modifying its sulfhydryl groups. In this study, the potential effects of juglone, also known as PIN1 inhibitor, on oral cancer and carcinogenesis were investigated at the molecular level. Materials and Methods: 4-Nitroquinoline N-oxide (4-NQO) was used to create an oral cancer model in animals. Wistar rats were divided into five groups: Control, NQO, Juglone, NQO+J, and NQO+J*. The control group received the basal diet and tap water throughout the experiment. The NQO group received 4-NQO for 8 weeks in drinking water only. The Juglone group was administered intraperitoneally in a juglone solution for 10 weeks (1 mg/kg/day). The NQO+J group received 4-NQO in drinking water for 8 weeks, starting 1 week after the cessation of 4-NQO treatment. They were then administered intraperitoneally in a juglone solution for 10 weeks. (1 mg/kg/day). NQO+J* group: received 4 NQO for 8 weeks in drinking water and administered intraperitoneally in a juglone solution for 10 weeks (1 mg/kg/day). They were sacrificed at the end of the 22-week experimental period. The tongue tissues of the rats were isolated after the experiment, morphological changes were investigated by histological examinations, and the molecular apoptotic process was investigated by rt-qPCR and western blot. Results: Histological results indicate that tumors are formed in the tongue tissue with 4-NQO, and juglone treatment largely corrects the epithelial changes that developed with 4-NQO. It has been determined that apoptotic factors p53, Bax, and caspases are induced by the effect of juglone, while antiapoptotic factors such as Bcl-2 are suppressed. However, it was observed that the positive effects were more pronounced in rats given juglone together with 4-NQO. Conclusions: The use of PIN1 inhibitors such as juglone in place of existing therapeutic approaches might be a promising and novel approach to the preservation and treatment of oral cancer and carcinogenesis. However, further research is required to investigate the practical application of such inhibitors.
1 August 2013 in Turkish Journal of Pediatric Surgery
Glioblastoma is a primary malignant brain tumor that can be treated with 1,3-bis(2-chloroethyl)-1-nitrosurea (BiCNU/carmustine). Resveratrol is a natural phenol that can interfere with apoptosis. This study aims to investigate how the combination of BiCNU and resveratrol affects glioblastoma cells in vitro. Accordingly, YKG1 glioblastoma cells were treated with different amounts of resveratrol (50 and 100 µM) and BiCNU (10 and 20 µM) either alone or in combination. Cell viability tests and immunochemical studies were conducted on these cells. According to results, increasing the amount of resveratrol and BiCNU decreased cell viability. Additionally, when these maximal doses of resveratrol and BiCNU (100 µM resveratrol plus 20 µM BiCNU) were applied, viability decreased to the highest cytotoxicity levels. Immunohistochemical analysis also revealed the significantly upregulated H scores of beclin-1 and caspase-3 in treated groups with the highest value in maximally combined concentration. These results indicated the cumulative effects of concurrent administration of BiCNU and resveratrol on the cytotoxicity of malignant human YKG1 glioblastoma cells in vitro.